Log In
BCIQ
Print this Print this
 

lenzilumab (KB003)

  Manage Alerts
Collapse Summary General Information
Company KaloBios Pharmaceuticals Inc.
DescriptionChimeric mAb against GM-CSF developed using Humaneered technology
Molecular Target Granulocyte macrophage colony-stimulating factor (GM-CSF) receptor (CSF2RA) (GMR) (CD116)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentIND
Standard IndicationChronic myelogenous leukemia (CML)
Indication DetailsTreat chronic monomyelocytic leukemia (CMML)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today